Skip to main content
$1.81 -$0.08 (-4.2%)

04:00 PM EST on 02/25/21

Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Current Price $1.81 Mkt Cap $586.8M
Open $1.89 P/E Ratio 0.00
Prev. Close $1.81 Div. (Yield) $0.00 (0.0%)
Daily Range $1.80 - $1.91 Volume 4,459,834
52-Wk Range $0.75 - $2.40 Avg. Daily Vol. 4,032,267

Caps

How do you think NASDAQ:GERN will perform against the market?

Add Stock to CAPS Watchlist

All Players

628 Outperform
61 Underperform
 

All-Star Players

77 Outperform
15 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:GERN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

streetdan (< 20)
Submitted September 09, 2018

This company has found an effective cancer treatment that has only a relatively small, easily managed toxicity. It is on the frontier of not only being a potential stand alone agent, but also may improve other cancer agents when used in combination.… More

SwingCorey (22.49)
Submitted January 11, 2010

Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem cells (e.g., from dental pulp, bone marrow, and… More

Recent Community Commentary

Read the most recent pitches from players about GERN.

Recs

0
Member Avatar KingGoat (< 20) Submitted: 2/20/2021 12:38:50 PM : Outperform Start Price: $1.94 NASDAQ:GERN Score: -6.37

Phase 3 study in progress.

Recs

0
Member Avatar LastPlaceLenny (67.25) Submitted: 3/15/2019 2:46:17 AM : Underperform Start Price: $1.66 NASDAQ:GERN Score: +27.25

Still waiting for my stocks to go to zero. Lost so much, no point cashing out now....

Recs

1
Member Avatar streetdan (< 20) Submitted: 9/9/2018 10:31:50 AM : Outperform Start Price: $6.15 NASDAQ:GERN Score: -102.98

This company has found an effective cancer treatment that has only a relatively small, easily managed toxicity. It is on the frontier of not only being a potential stand alone agent, but also may improve other cancer agents when used in combination. They have therefore an agent that can disrupt cancers progression without significant harm to normal cells.

Leaderboard

Find the members with the highest scoring picks in GERN.

Score Leader

SheepInvstr213

SheepInvstr213 (< 20) Score: +563.74

The Score Leader is the player with the highest score across all their picks in GERN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SheepInvstr213 < 20 3/9/2009 Underperform 5Y $4.59 -60.58% +468.98% +529.57 0 Comment
epc53 26.92 3/3/2009 Underperform NS $3.85 -52.99% +452.08% +505.07 0 Comment
Dudeone 64.38 3/12/2009 Underperform 5Y $4.32 -58.10% +422.82% +480.92 0 Comment
e2003 91.09 3/30/2009 Underperform 1Y $4.75 -61.89% +384.51% +446.41 0 Comment
kevleeyang 70.77 1/23/2009 Underperform NS $7.23 -74.97% +369.38% +444.35 0 Comment
js2776 < 20 1/26/2009 Underperform 3Y $8.15 -77.79% +364.95% +442.74 2 Comments
yourfavoritepers 85.49 1/26/2009 Underperform 3W $7.47 -75.77% +365.45% +441.22 0 Comment
dcfoolz 72.89 1/26/2009 Underperform 5Y $7.47 -75.77% +365.45% +441.22 0 Comment
Lafleur526 31.50 1/26/2009 Underperform 3W $7.47 -75.77% +365.45% +441.22 0 Comment
SheepInvstr321 96.56 1/23/2009 Underperform 5Y $7.36 -75.41% +364.67% +440.08 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GERN.